关注
Kartik Sehgal
Kartik Sehgal
Dana-Farber Cancer Institute
在 dfci.harvard.edu 的电子邮件经过验证
标题
引用次数
引用次数
年份
Post-acute COVID-19 syndrome
A Nalbandian, K Sehgal, A Gupta, MV Madhavan, C McGroder, ...
Nature medicine 27 (4), 601-615, 2021
45812021
Extrapulmonary manifestations of COVID-19
A Gupta, MV Madhavan, K Sehgal, N Nair, S Mahajan, TS Sehrawat, ...
Nature medicine 26 (7), 1017-1032, 2020
34642020
Pharmacological agents targeting thromboinflammation in COVID-19: review and implications for future research
B Bikdeli, MV Madhavan, A Gupta, D Jimenez, JR Burton, ...
Thrombosis and haemostasis 120 (07), 1004-1024, 2020
2942020
Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets
K Sehgal, R Das, L Zhang, R Verma, Y Deng, M Kocoglu, J Vasquez, ...
Blood, The Journal of the American Society of Hematology 125 (26), 4042-4051, 2015
1332015
Targeting human dendritic cells in situ to improve vaccines
K Sehgal, KM Dhodapkar, MV Dhodapkar
Immunology letters 162 (1), 59-67, 2014
1092014
Association of performance status with survival in patients with advanced non–small cell lung cancer treated with pembrolizumab monotherapy
K Sehgal, RR Gill, P Widick, P Bindal, DC McDonald, M Shea, ...
JAMA network open 4 (2), e2037120-e2037120, 2021
982021
Safety and efficacy of PD-1 inhibitors among HIV-positive patients with non–small cell lung cancer
L Ostios-Garcia, J Faig, GC Leonardi, AE Adeni, SJ Subegdjo, CA Lydon, ...
Journal of Thoracic Oncology 13 (7), 1037-1042, 2018
922018
Targeting ROS1 rearrangements in non-small cell lung cancer with crizotinib and other kinase inhibitors
K Sehgal, R Patell, D Rangachari, DB Costa
Translational cancer research 7 (Suppl 7), S779, 2018
572018
Nanoparticle-mediated combinatorial targeting of multiple human dendritic cell (DC) subsets leads to enhanced T cell activation via IL-15–dependent DC crosstalk
K Sehgal, R Ragheb, TM Fahmy, MV Dhodapkar, KM Dhodapkar
The Journal of Immunology 193 (5), 2297-2305, 2014
512014
Dynamic single-cell RNA sequencing identifies immunotherapy persister cells following PD-1 blockade
K Sehgal, A Portell, EV Ivanova, PH Lizotte, NR Mahadevan, JR Greene, ...
The Journal of clinical investigation 131 (2), 2021
422021
Small cell transformation of non-small cell lung cancer on immune checkpoint inhibitors: uncommon or under-recognized?
K Sehgal, A Varkaris, H Viray, PA VanderLaan, D Rangachari, DB Costa
Journal for Immunotherapy of Cancer 8 (1), 2020
402020
Plasmacytoid dendritic cells, interferon signaling, and FcγR contribute to pathogenesis and therapeutic response in childhood immune thrombocytopenia
K Sehgal, X Guo, S Koduru, A Shah, A Lin, X Yan, KM Dhodapkar
Science translational medicine 5 (193), 193ra89-193ra89, 2013
332013
Association of pretreatment circulating tumor tissue–modified viral HPV DNA with clinicopathologic factors in HPV-positive oropharyngeal cancer
EM Rettig, AA Wang, NA Tran, E Carey, T Dey, JD Schoenfeld, K Sehgal, ...
JAMA Otolaryngology–Head & Neck Surgery 148 (12), 1120-1130, 2022
282022
Cases of ROS1-rearranged lung cancer: when to use crizotinib, entrectinib, lorlatinib, and beyond?
K Sehgal, AJ Piper-Vallillo, H Viray, AM Khan, D Rangachari, DB Costa
Precision cancer medicine 3, 2020
272020
Association between immune-related adverse events and clinical outcomes to programmed cell death protein 1/programmed death-ligand 1 blockade in SCLC
B Ricciuti, AR Naqash, J Naidoo, K Sehgal, A Miller, K Kehl, ...
JTO Clinical and Research Reports 1 (4), 100074, 2020
23*2020
Clinical Benefit of Tyrosine Kinase Inhibitors in Advanced Lung Cancer with EGFR‐G719A and Other Uncommon EGFR Mutations
K Sehgal, D Rangachari, PA VanderLaan, SS Kobayashi, DB Costa
The oncologist, 2020
202020
Hyperprogression in patients with cancer receiving immune checkpoint inhibitors
K Sehgal
JAMA Network Open 4 (3), e211839-e211839, 2021
182021
Extended-interval dosing strategy of immune checkpoint inhibitors in lung cancer: will it outlast the COVID-19 pandemic?
K Sehgal, DB Costa, D Rangachari
Frontiers in Oncology 10, 1193, 2020
172020
Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Non–small-cell Lung Cancer
K Sehgal, A Bulumulle, H Brody, RR Gill, S Macherla, A Qilleri, ...
Clinical lung cancer 22 (3), e379-e389, 2021
142021
Additional Oncogenic Alterations in RAS-Driven Differentiated Thyroid Cancers Associate with Worse Clinicopathologic Outcomes
A Bikas, S Ahmadi, T Pappa, E Marqusee, K Wong, MA Nehs, NL Cho, ...
Clinical Cancer Research 29 (14), 2678-2685, 2023
82023
系统目前无法执行此操作,请稍后再试。
文章 1–20